CHD

Business Context and Reporting Period

Company: Church & Dwight Co., Inc.
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three months ended April 2, 2004
Business Overview: The Company operates through four primary segments: C&D Consumer (deodorizing, cleaning, laundry, personal care), Armkel LLC (personal care, 50% owned), C&D Specialty Products Division (specialty chemicals), and Other Equity Affiliates. The Company is a Delaware corporation with principal executive offices in Princeton, N.J.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 19.2% ($47.7 million) driven primarily by the acquisition of the former Unilever oral care business (approx. $30 million), six extra days in the fiscal quarter, and favorable foreign exchange rates.
• Margin Expansion: Gross margin improved to 32.6% from 29.7%, attributed to the higher-margin oral care products and reduced trade/consumer promotion spending.
• Expense Increases: Marketing expenses rose $7.2 million due to advertising for household deodorizing and oral care products. SG&A increased $5.8 million due to higher sales volume, tradename amortization, performance-based compensation, and Sarbanes-Oxley compliance costs.
• Debt Reduction: Total debt decreased by approximately $32.6 million compared to the prior year-end, with significant repayments of long-term debt ($32.6 million) offset by short-term borrowing activity.
• Segment Performance:
  • C&D Consumer: Sales up 20% to $245.1 million; Income before taxes up 42.9% to $29.5 million.
  • Armkel LLC: Sales up 14.1% to $113.8 million; Income before taxes up 33.7% to $21.7 million.
  • Specialty Products: Sales up 15.6% to $50.9 million; Income before taxes up 63.1% to $5.4 million.

Outlook, Risks, and Unusual Items

• Subsequent Event (Armkel Acquisition): On May 6, 2004, the Company announced a non-binding agreement to purchase Kelso & Company's 50% interest in Armkel LLC for approximately $254 million. The transaction is expected to close around May 30, 2004.
  • Financing: The Company expects to raise $640 million in medium-term borrowing to finance the deal and replace existing facilities.
  • Impact on Earnings: Completion will trigger non-cash accounting charges (inventory revaluation, write-off of deferred financing costs) expected to adversely affect earnings in Q2 and Q3 2004.
• Liquidity and Covenants: The Company maintains a leverage ratio of 2.16 (max 3.00) and an interest coverage ratio of 6.86 (min 5.0), comfortably meeting credit facility covenants.
• Legal Contingencies:
  • Carter-Wallace Litigation: Potential liability up to $2.1 million regarding indemnification for shareholder appraisal proceedings.
  • Fleming Companies Bankruptcy: Customer Fleming filed for bankruptcy and sued for approx. $4.2 million in preference payments. Management believes the ultimate liability will not be material.
• Accounting Pronouncements: The Company has not yet reflected the effects of the Medicare Prescription Drug Act (FSP No. 106-1) on its post-retirement health care plan, pending further guidance, though impact is not expected to be material.

Investor Verification Checklist

• Armkel Acquisition Status: Verify the final closing date and financing terms for the $254 million purchase of the remaining 50% of Armkel LLC.
• Q2/Q3 Earnings Impact: Monitor the magnitude of non-cash charges related to the Armkel acquisition in the upcoming quarters.
• Debt Structure: Confirm the execution of the new $640 million medium-term borrowing facility and the resulting interest rate environment.
• Legal Outcomes: Track the resolution of the Fleming Companies bankruptcy litigation and the Carter-Wallace shareholder appraisal proceedings.
• Oral Care Integration: Assess the sustained performance of the acquired Unilever oral care brands beyond the initial acquisition boost.